drugset / Trial / NCT04676126

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

NCT04676126 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to prospectively analyze changes in macular pigment optical density and dermal carotenoid levels as they relate to visual field function in patients prescribed a macular pigment-containing medical food (Lumega-Z), in combination with a topical carbonic anhydrase inhibitor.

Timeline

Start
2021-05
Primary completion
2022-05
Completion
2022-05

Outcome

Outcome not reported

Stopped (Enrollment): “IRB records show administrative closure on 12/16/21. No subjects enrolled.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dorzolamide Small molecule 2 % Topical

Indications